SABIO-GROUP
26.3.2018 11:02:10 CEST | Business Wire | Press release
Avaya (NYSE:AVYA) today recognised customer experience solutions expert Sabio as its first EMEA and APAC partner to achieve full Avaya Oceana Accreditation. This confirms Sabio’s ability to sell, design, implement and support complex customer journey solutions based on the next generation Avaya Oceana omnichannel customer engagement solution, and acknowledges Sabio as one of Avaya’s leading specialist global CX partners.
The accreditation demonstrates Sabio’s deep Avaya solutions expertise, as confirmed by its success in winning Avaya’s 2017 Contact Centre Partner of the Year Award, and securing the prestigious Project of the Year Award. Sabio won due to its success in deploying one of the world’s largest Avaya Oceana projects for a major European omnichannel retailer.
“Oceana is critical to helping our customers achieve their digital transformation goals, so we’re delighted to recognise Sabio’s CX vision and global capabilities and award full Avaya Oceana accreditation,” said Nidal Abou-Ltaif, President of Avaya International. “In addition to securing all the necessary Oceana certifications, Sabio has also seized the commercial initiative, successfully deploying Oceana to deliver seamless customer engagement for one of Europe’s largest retailers.”
“Becoming the EMEA and APAC regions’ first fully certified and accredited Avaya Oceana partner illustrates both Sabio’s in-depth capabilities as well as its determination to support Avaya in driving the Oceana vision,” added Ioan MacRae, Avaya UK’s Managing Director. “Sabio doesn’t just talk about CX and customer journey innovation, it’s a partner that always delivers, as evidenced by its recent 2017 Project of the Year Award Oceana deployment.”
“Sabio is committed to delivering brilliant customer experiences across the customer journey, so being fully accredited to offer Avaya Oceana significantly strengthens our proposition,” added Sabio’s Chief Commercial Officer, Russell Sheldon. “This latest Avaya accreditation confirms Sabio as the ideal partner for major Oceana deployments.”
About Sabio Group:
Sabio Group, which includes Sabio, DatapointEurope and Bright UK, delivers solutions and services that seamlessly combine digital and human interactions to support outstanding customer experiences. The group works with major brands worldwide, including the AA, AXA Assistance, BGL, BNP Paribas, DHL, HomeServe, Saga, Sainsbury’s Argos, Telefónica, Transcom Worldwide and Yorkshire Building Society. www.sabio.co.uk
View source version on businesswire.com: https://www.businesswire.com/news/home/20180326005269/en/
Contact:
PR for Sabio
Cheryl Billson, +44 (0)7791 720460
cheryl.billson@commacomms.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom